A Study to Evaluate the Safety, Tolerance, and Pharmacokinetic and Pharmacodynamic Profile Of 1 SR Formulation of EB-1020

NCT01744808 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

54

Enrollment

INDUSTRY

Sponsor class

Conditions

Normal, Healthy Volunteers

Interventions

DRUG: EB-1020 IR
DRUG: EB-1020 SR1
DRUG: EB-1020 SR2
DRUG: EB-1020 SR3
OTHER: Placebo

Sponsor

Otsuka Pharmaceutical Development & Commercialization, Inc.